My comment on blog post: Just one correction in an otherwise great article -- it is very unlikely that CTIX will need dilutive financing. They have 11 million bucks in the bank and have stated that they have enough cash for a year. By that time several of these trials will have concluded and the CEO can follow through on his stated goal of partnership deals. The results on the antibiotic (Brilacidin) have been so good, with fewer and less severe side effects than many current antibiotics, that it is hard to imagine a scenario other than FDA approval. The cancer drug (Kevetrin) has also shown such good results that a partnership deal is a very reasonable goal. The remaining two trials just started recently so we don't know yet how they are going -- but they should be relatively quick in getting results so we should know something within months, and certainly within a year.

http://seekingalpha.com/instablog/21116141-el...cellceutix